Table 4.
Baseline laboratory and therapeutic data for sustained response versus relapse after end-of-treatment response by univariate analysis.
| Variable | Sustained response (n=66) | Relapse after ETVR (n=30) | P value |
|---|---|---|---|
| Age (years) | 45.5 (13.5) | 53.6 (11.6) | .005 |
| BMI (kg/m2) | 27.2 (5.2) | 27.0 (5.8) | |
| WBC (×109/L) | 6.3 (2.1) | 5.7 (2.4) | .87 |
| Hemoglobin (g/L) | 142.6 (19.7) | 137.1 (18.2) | .23 |
| Platelets (×109/L) | 256.6 (115.1) | 239.1 (101.4) | .21 |
| Prothrombin time (seconds) | 13.6 (4.2) | 12.9 (1.2) | .48 |
| Bilirubin (μmol/L) | 15.3 (20.5) | 14.1 (15.2) | .39 |
| Albumin (g/L) | 40.0 (3.7) | 38.0 (4.6) | .028 |
| ALT (IU/L) | 88.4 (89.0) | 90.9 (63.3) | .89 |
| AST (IU/L) | 59.9 (44.4) | 82.3 (56.4) | .04 |
| GGT (IU/L) | 90.4 (66.1) | 122.5 (95.9) | .94 |
| ALP (IU/L) | 108.2 (91.6) | 108.3 (40.0) | .99 |
| Creatinine (μmol/L) | 109.0 (146.5) | 109.6 (156.4) | .99 |
| Cholesterol (mmol/L) | 3.2 (1.4) | 3.1 (0.9) | .83 |
| AFP (IU/L) | 5.4 (45.4) | 15.9 (36.5) | .026 |
| TSH (IU/L) | 3.3 (6.9) | 3.3 (4.6) | .63 |
| Baseline HCV load (copy/mL) | 5.4×106 (7.8×106) | 3.7×106 (4.9×106) | .30 |
| HCV load (week 12) (copy/mL) | 1.1×106 (1.9×106) | 0.6×106 (0.7×106) | .33 |
| Ribavirin dose (mg/day) | 923.9 (123.3) | 906.9 (155.4) | .28 |
| peg-INF dose (μg/week) | 177.2 (13.5) | 180.0 (0.0) | .27 |
| Ribavirin dose (mg/kg/day) | 12.9 (2.6) | 12.7 (2.4) | .77 |
| Peginterferon dose (μg/kg/week) | 2.5 (0.6) | 2.8 (0.9) | .13 |
Data are expressed as mean±SD. NS: not significant ALT: alanine aminotransferase, AST: aspartate aminotransferase, ALP: alkaline phosphatase, GGT: γ-glutamyl transferase, INR: international normalization ratio, AFP: alpha-fetoprotein, HCV: hepatitis C virus, PEG-INF: pegylated interferon.